Reduction in Total Cardiovascular Events With the PCSK9 Inhibitor Evolocumab in Patients With Cardiovascular Disease in the FOURIER Trial

被引：0
|
作者：
Murphy, Sabina A.
Pedersen, Terje R.
Gaciong, Zbigniew A.
Ceska, Richard
Ezhov, Marat V.
Connolly, Derek
Kraydashenko, Oleg
Jukema, J. Wouter
Toth, Kalman
Tikkanen, Matti J.
Im, Kyungah
Wiviott, Stephen D.
Kurtz, Christopher
Honarpour, Narimon
Giugliano, Robert P.
Keech, Anthony C.
Sever, Peter S.
Sabatine, Marc S.
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
LDLPCSK9;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15100
引用
收藏
页数：1
相关论文
共 50 条
  • [41] PCSK9 inhibitor therapy and guideline treatment targets for cardiovascular disease and familial hypercholesterolaemia
    Suresh, A.
    Theodoraki, A.
    Ward, E.
    Feher, M. D.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2945 - 2945
  • [42] Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
    Bhatt, D.
    Khan, I
    Koumas, A.
    Filardi, P. P.
    Fernandez, J. T.
    Marx, N.
    Cabezas, M. C.
    Andrade, K.
    Potukuchi, P.
    Pereira, C.
    Garon, G.
    Tokgozoglu, L.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [43] PCSK9 inhibitors and cardiovascular outcomes
    Steffens, Daniel
    Bramlage, Peter
    Scheeff, Celine
    Kasner, Mario
    Hassanein, Adel
    Friebel, Julian
    Rauch-Kroehnert, Ursula
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 35 - 47
  • [44] Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
    Pastori, Daniele
    Nocella, Cristina
    Farcomeni, Alessio
    Bartimoccia, Simona
    Santulli, Maria
    Vasaturo, Fortunata
    Carnevale, Roberto
    Menichelli, Danilo
    Violi, Francesco
    Pignatelli, Pasquale
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (12) : 1455 - 1462
  • [45] Atherosclerosis PCSK9 inhibition reduces cardiovascular events in high-risk patients
    Huynh, Karina
    NATURE REVIEWS CARDIOLOGY, 2017, 14 (05) : 2 - 2
  • [46] CIRCULATING PCSK9 LEVEL PREDICTS RISK OF CARDIOVASCULAR EVENTS AND DEATH IN HEMODIALYSIS PATIENTS
    Hwang, Hyeon Seok
    Kim, Jin Sug
    Kim, Yang-Gyun
    Lee, So-Young
    Ahn, Shin Young
    Lee, Hong Joo
    Lees, Dong-Young
    Lee, Sang ho
    Moon, Ju-Young
    Jeong, Kyung Hwan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 91 - 91
  • [47] PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9
    Tavori, Hagai
    Giunzioni, Ilaria
    Fazio, Sergio
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2015, 22 (02) : 126 - 132
  • [48] PCSK9 inhibition, a potential target to reduce cardiovascular events in patients with familial hypercholesterolemia
    Marques, Patrice
    Domingo, Elena
    Rubio, Arantxa
    Martinez-Hervas, Sergio
    Piqueras, Laura
    Tomas Real, Jose
    Francisco Ascaso, Juan
    Jesus Sanz, Maria
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 35 - 35
  • [49] EXPERIENCE OF THE USE OF THE PCSK9 INHIBITOR ALIROCUMAB IN PATIENTS WITH EXTREMELY HIGH CARDIOVASCULAR RISK
    Korneva, V. A.
    Kuznetsova, T. Y.
    Scopetc, I. S.
    Vezikova, N. N.
    KARDIOLOGIYA, 2020, 60 (08) : 71 - 77
  • [50] Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease
    Dave L. Dixon
    Lauren G. Pamulapati
    John D. Bucheit
    Evan M. Sisson
    Shawn R. Smith
    Caroline J. Kim
    George F. Wohlford
    Jonah Pozen
    Current Atherosclerosis Reports, 2019, 21
12345